Table 4.

Response to first-line treatment

Treatment groupComplete remission, n (%)Remission duration, median (range), moRelapse rate, n (%) of CR patientsHCT, n (%) of CR patients
AML-like (n = 19) 13 (68.4) 68 (4-399)* 4 (28.5) 7 (2 auto) (36.8-53.8) 
ALL-like (n = 19) 15 (78.9) 47 (6-224) 5 (33.3) 7 (46.7) 
Aspa-MTX (n = 16) 12 (75) 26 (5-166) 4 (33.3) 6 (37.5-50) 
CHOP-like (n = 16) 6 (37.5) 17 (4-22)* 4 (66.7) 2 (12.5-33.3) 
NOS (n = 10) 35 
Treatment groupComplete remission, n (%)Remission duration, median (range), moRelapse rate, n (%) of CR patientsHCT, n (%) of CR patients
AML-like (n = 19) 13 (68.4) 68 (4-399)* 4 (28.5) 7 (2 auto) (36.8-53.8) 
ALL-like (n = 19) 15 (78.9) 47 (6-224) 5 (33.3) 7 (46.7) 
Aspa-MTX (n = 16) 12 (75) 26 (5-166) 4 (33.3) 6 (37.5-50) 
CHOP-like (n = 16) 6 (37.5) 17 (4-22)* 4 (66.7) 2 (12.5-33.3) 
NOS (n = 10) 35 
*

Data are missing for 1 patient.